STRO
Sutro Biopharma, Inc.
Price Chart
Latest Quote
$29.63
+1.22 (+4.29%)
Current Price
| Previous Close | $28.41 |
| Open | $28.70 |
| Day High | $29.90 |
| Day Low | $27.69 |
| Volume | 230,492 |
Stock Information
| Shares Outstanding | 16.57M |
| Total Debt | $13.63M |
| Cash Equivalents | $202.56M |
| Revenue | $99.61M |
| Net Income | $-153.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $490.98M |
| EPS (TTM) | $-16.35 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $277.86M |
| Sales | $99.61M |
| Income | $-153.60M |
| Book/sh | $-4.04 |
| Cash/sh | $12.22 |
| Employees | 133 |
Financial Ratios
| Quick Ratio | 3.04 |
| Current Ratio | 3.12 |
Returns & Margins
| ROA | -19.32% |
| Gross Margin | -65.58% |
| Operating Margin | -203.91% |
| Profit Margin | -154.21% |
Ownership
| Insider Ownership | 2.26% |
| Institutional Ownership | 86.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.30 |
| P/S | 4.93 |
| P/B | -7.34 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $48.31 |
Technical Indicators
| SMA20 | $27.79 |
| SMA50 | $31.81 |
| SMA200 | $18.04 |
| RSI | 50.97 |
| ATR | 2.9071 |
| Shares Float | 10.30M |
| Short Float | 4.55% |
| Short Ratio | 2.35 |
| Volatility | 1.55 |
| Rel Volume | 0.93 |
Performance History
| Week | +11.90% |
| Month | -6.44% |
| Quarter | +40.29% |
| 6 Months | +202.04% |
| YTD | +170.35% |
| Year | +275.06% |
| 3 Years | -46.61% |
| 5 Years | -84.04% |
| 10 Years | -80.51% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $29.63 | 287,900 |
| 2026-06-17 | $28.41 | 499,900 |
| 2026-06-16 | $28.17 | 344,100 |
| 2026-06-15 | $30.20 | 188,600 |
| 2026-06-12 | $28.80 | 148,300 |
| 2026-06-11 | $26.48 | 238,900 |
| 2026-06-10 | $26.09 | 197,000 |
| 2026-06-09 | $25.79 | 158,800 |
| 2026-06-08 | $25.41 | 169,900 |
| 2026-06-05 | $26.09 | 295,700 |
| 2026-06-04 | $28.68 | 250,100 |
| 2026-06-03 | $27.18 | 435,300 |
| 2026-06-02 | $24.43 | 332,400 |
| 2026-06-01 | $28.25 | 216,200 |
| 2026-05-29 | $29.23 | 212,100 |
| 2026-05-28 | $29.63 | 188,800 |
| 2026-05-27 | $29.69 | 321,500 |
| 2026-05-26 | $27.38 | 643,000 |
| 2026-05-22 | $25.57 | 708,100 |
| 2026-05-21 | $30.62 | 364,700 |
| 2026-05-20 | $31.13 | 374,100 |
| 2026-05-19 | $31.67 | 729,500 |
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
đ° Latest News
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Motley Fool âĸ 2026-05-31T14:39:50Z
Barclays initiates oncology-focused biotechs with positive outlook
Investing.com âĸ 2026-05-28T15:26:11ZNews Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Simply Wall St. âĸ 2026-05-28T11:19:15Z
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results
Simply Wall St. âĸ 2026-05-17T13:02:32Z
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-06T22:30:22Z
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-05T14:00:04Z
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program
Insider Monkey âĸ 2026-05-01T08:17:32Z
Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-04-30T13:36:40Z
Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now
Insider Monkey âĸ 2026-04-29T17:00:28Z
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Zacks âĸ 2026-04-08T12:31:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $102,484,000 | $62,043,000 | $153,731,000 | $67,772,000 |
| Operating Revenue | $102,484,000 | $62,043,000 | $153,731,000 | $67,772,000 |
| Expenses | ||||
| Interest Expense | $42,063,000 | $31,070,000 | $23,750,000 | $3,346,000 |
| Total Expenses | $207,436,000 | $300,496,000 | $243,009,000 | $196,715,000 |
| Other Income Expense | $-53,415,000 | - | $9,917,000 | $12,130,000 |
| Net Non Operating Interest Income Expense | $-32,812,000 | $13,355,000 | $-9,240,000 | $109,000 |
| Interest Expense Non Operating | $42,063,000 | $31,070,000 | $23,750,000 | $3,346,000 |
| Operating Expense | $207,436,000 | $300,496,000 | $243,009,000 | $196,715,000 |
| General And Administrative Expense | $41,019,000 | $48,453,000 | $62,584,000 | $59,544,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Net Interest Income | $-32,812,000 | $13,355,000 | $-9,240,000 | $109,000 |
| Interest Income | $9,251,000 | $44,425,000 | $14,510,000 | $3,455,000 |
| Normalized Income | $-137,724,415 | $-227,461,000 | $-114,627,430 | $-128,786,700 |
| Net Income From Continuing And Discontinued Operation | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Total Operating Income As Reported | $-158,367,000 | $-238,453,000 | $-89,278,000 | $-128,943,000 |
| Net Income Common Stockholders | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Net Income | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Net Income Including Noncontrolling Interests | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Net Income Continuous Operations | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Pretax Income | $-191,179,000 | $-225,098,000 | $-88,601,000 | $-116,704,000 |
| Special Income Charges | $-53,415,000 | $0 | - | - |
| Interest Income Non Operating | $9,251,000 | $44,425,000 | $14,510,000 | $3,455,000 |
| Operating Income | $-104,952,000 | $-238,453,000 | $-89,278,000 | $-128,943,000 |
| Per Share | ||||
| Diluted EPS | $-22.49 | $-29.40 | $-17.80 | $-23.50 |
| Basic EPS | $-22.49 | $-29.40 | $-17.80 | $-23.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $-53,415 | $0 | $2,082,570 | $2,547,300 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-88,377,000 | $-186,810,000 | $-67,952,000 | $-119,798,000 |
| Total Unusual Items | $-53,415,000 | $0 | $9,917,000 | $12,130,000 |
| Total Unusual Items Excluding Goodwill | $-53,415,000 | $0 | $9,917,000 | $12,130,000 |
| Reconciled Depreciation | $7,324,000 | $7,218,000 | $6,816,000 | $5,690,000 |
| EBITDA (Bullshit earnings) | $-141,792,000 | $-186,810,000 | $-58,035,000 | $-107,668,000 |
| EBIT | $-149,116,000 | $-194,028,000 | $-64,851,000 | $-113,358,000 |
| Diluted Average Shares | $8,497,798 | $7,736,734 | $6,016,354 | $5,073,918 |
| Basic Average Shares | $8,497,798 | $7,736,734 | $6,016,354 | $5,073,918 |
| Diluted NI Availto Com Stockholders | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Tax Provision | $-93,000 | $2,363,000 | $18,192,000 | $2,500,000 |
| Restructuring And Mergern Acquisition | $53,415,000 | $0 | - | - |
| Research And Development | $166,417,000 | $252,043,000 | $180,425,000 | $137,171,000 |
| Selling General And Administration | $41,019,000 | $48,453,000 | $62,584,000 | $59,544,000 |
| Other Gand A | $41,019,000 | $48,453,000 | $62,584,000 | $59,544,000 |
| Gain On Sale Of Security | - | - | $9,917,000 | $12,130,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-132,452,000 | $44,601,000 | $149,649,000 | $217,048,000 |
| Total Assets | $173,830,000 | $387,207,000 | $470,736,000 | $406,944,000 |
| Total Non Current Assets | $22,904,000 | $43,897,000 | $49,194,000 | $53,791,000 |
| Other Non Current Assets | $1,353,000 | $8,030,000 | $4,439,000 | $2,727,000 |
| Current Assets | $150,926,000 | $343,310,000 | $421,542,000 | $353,153,000 |
| Other Current Assets | $5,521,000 | $17,799,000 | $9,846,000 | $11,667,000 |
| Receivables | $3,977,000 | $8,616,000 | $36,078,000 | $7,122,000 |
| Accounts Receivable | $3,977,000 | $8,616,000 | $36,078,000 | $7,122,000 |
| Cash Cash Equivalents And Short Term Investments | $141,428,000 | $316,895,000 | $375,618,000 | $334,364,000 |
| Cash And Cash Equivalents | $58,130,000 | $190,304,000 | $69,268,000 | $47,254,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Cash Equivalents | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $15,674,000 | $23,154,000 | $33,635,000 | $50,430,000 |
| Long Term Debt And Capital Lease Obligation | $7,891,000 | $15,674,000 | $23,154,000 | $33,345,000 |
| Current Debt And Capital Lease Obligation | $7,783,000 | $7,480,000 | $10,481,000 | $17,085,000 |
| Current Debt | - | - | $4,061,000 | $12,500,000 |
| Other Current Borrowings | - | - | $4,061,000 | $12,500,000 |
| Long Term Debt | - | - | - | $3,771,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $306,282,000 | $342,606,000 | $321,087,000 | $189,896,000 |
| Total Non Current Liabilities Net Minority Interest | $231,149,000 | $210,713,000 | $227,341,000 | $123,349,000 |
| Other Non Current Liabilities | $1,694,000 | $1,694,000 | $1,694,000 | $119,000 |
| Non Current Deferred Liabilities | $221,564,000 | $193,345,000 | $202,493,000 | $89,885,000 |
| Current Liabilities | $75,133,000 | $131,893,000 | $93,746,000 | $66,547,000 |
| Other Current Liabilities | $2,913,000 | $4,009,000 | $3,897,000 | $3,080,000 |
| Current Deferred Liabilities | $10,562,000 | $69,783,000 | $20,666,000 | $16,759,000 |
| Payables And Accrued Expenses | $39,233,000 | $37,716,000 | $44,016,000 | $16,481,000 |
| Payables | $7,565,000 | $10,493,000 | $24,605,000 | $4,797,000 |
| Total Tax Payable | $0 | $18,000 | $15,165,000 | $0 |
| Accounts Payable | $7,565,000 | $10,475,000 | $9,440,000 | $4,797,000 |
| Equity | ||||
| Common Stock Equity | $-132,452,000 | $44,601,000 | $149,649,000 | $217,048,000 |
| Total Equity Gross Minority Interest | $-132,452,000 | $44,601,000 | $149,649,000 | $217,048,000 |
| Stockholders Equity | $-132,452,000 | $44,601,000 | $149,649,000 | $217,048,000 |
| Gains Losses Not Affecting Retained Earnings | $19,000 | $39,000 | $21,000 | $-618,000 |
| Other Equity Adjustments | $19,000 | $39,000 | $21,000 | $-618,000 |
| Retained Earnings | $-977,955,000 | $-786,869,000 | $-559,408,000 | $-452,615,000 |
| Other | ||||
| Ordinary Shares Number | $8,584,309 | $8,252,643 | $6,100,982 | $5,749,954 |
| Share Issued | $8,584,309 | $8,252,643 | $6,100,982 | $5,749,954 |
| Tangible Book Value | $-132,452,000 | $44,601,000 | $149,649,000 | $217,048,000 |
| Invested Capital | $-132,452,000 | $44,601,000 | $153,710,000 | $233,319,000 |
| Working Capital | $75,793,000 | $211,417,000 | $327,796,000 | $286,606,000 |
| Capital Lease Obligations | $15,674,000 | $23,154,000 | $29,574,000 | $34,159,000 |
| Total Capitalization | $-132,452,000 | $44,601,000 | $149,649,000 | $220,819,000 |
| Additional Paid In Capital | $845,475,000 | $831,423,000 | $708,975,000 | $670,223,000 |
| Capital Stock | $9,000 | $8,000 | $61,000 | $58,000 |
| Common Stock | $9,000 | $8,000 | $61,000 | $58,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $221,564,000 | $193,345,000 | $202,493,000 | $89,885,000 |
| Long Term Capital Lease Obligation | $7,891,000 | $15,674,000 | $23,154,000 | $29,574,000 |
| Current Deferred Revenue | $10,562,000 | $69,783,000 | $20,666,000 | $16,759,000 |
| Current Capital Lease Obligation | $7,783,000 | $7,480,000 | $6,420,000 | $4,585,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,642,000 | $12,905,000 | $14,686,000 | $13,142,000 |
| Current Accrued Expenses | $31,668,000 | $27,223,000 | $19,411,000 | $11,684,000 |
| Net PPE | $21,551,000 | $35,867,000 | $44,755,000 | $51,064,000 |
| Accumulated Depreciation | $-27,352,000 | $-48,630,000 | $-42,163,000 | $-37,905,000 |
| Gross PPE | $48,903,000 | $84,497,000 | $86,918,000 | $88,969,000 |
| Leases | $12,343,000 | $24,205,000 | $23,606,000 | $23,215,000 |
| Construction In Progress | $151,000 | $497,000 | $497,000 | $1,685,000 |
| Other Properties | $34,824,000 | $57,928,000 | $60,821,000 | $62,286,000 |
| Machinery Furniture Equipment | $1,585,000 | $1,867,000 | $1,994,000 | $1,783,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $83,298,000 | $126,591,000 | $306,350,000 | $287,110,000 |
| Treasury Shares Number | - | - | $0 | - |
| Investments And Advances | - | - | - | $0 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-178,926,000 | $-194,638,000 | $-115,931,000 | $-4,309,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-177,231,000 | $-191,540,000 | $-111,616,000 | $3,549,000 |
| Cash Flow From Continuing Operating Activities | $-177,231,000 | $-191,540,000 | $-111,616,000 | $3,549,000 |
| Operating Gains Losses | - | $-32,139,000 | - | $-4,074,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,695,000 | $-3,098,000 | $-4,315,000 | $-7,858,000 |
| Investing Cash Flow | $45,013,000 | $218,508,000 | $-3,924,000 | $-35,022,000 |
| Cash Flow From Continuing Investing Activities | $45,013,000 | $218,508,000 | $-3,924,000 | $-35,022,000 |
| Net Other Investing Changes | - | - | - | $9,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $96,527,000 | $11,971,000 | $56,270,000 |
| Financing Cash Flow | $44,000 | $94,054,000 | $137,554,000 | $48,313,000 |
| Cash Flow From Continuing Financing Activities | $44,000 | $94,054,000 | $137,554,000 | $48,313,000 |
| Net Other Financing Charges | $-332,000 | $-509,000 | $135,718,000 | $-463,000 |
| Net Common Stock Issuance | $0 | $96,527,000 | $11,971,000 | $56,270,000 |
| Common Stock Issuance | $0 | $96,527,000 | $11,971,000 | $56,270,000 |
| Repurchase Of Capital Stock | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-4,083,000 | $-12,500,000 | $-9,375,000 |
| Interest Paid Supplemental Data | $0 | $310,000 | $1,126,000 | $1,869,000 |
| End Cash Position | $58,988,000 | $191,162,000 | $70,140,000 | $48,126,000 |
| Beginning Cash Position | $191,162,000 | $70,140,000 | $48,126,000 | $31,286,000 |
| Changes In Cash | $-132,174,000 | $121,022,000 | $22,014,000 | $16,840,000 |
| Proceeds From Stock Option Exercised | $376,000 | $2,119,000 | $2,365,000 | $1,881,000 |
| Net Issuance Payments Of Debt | $0 | $-4,083,000 | $-12,500,000 | $-9,375,000 |
| Net Long Term Debt Issuance | $0 | $-4,083,000 | $-12,500,000 | $-9,375,000 |
| Long Term Debt Payments | $0 | $-4,083,000 | $-12,500,000 | $-9,375,000 |
| Net Investment Purchase And Sale | $46,708,000 | $221,606,000 | $391,000 | $-27,173,000 |
| Sale Of Investment | $311,658,000 | $683,127,000 | $460,692,000 | $189,498,000 |
| Purchase Of Investment | $-264,950,000 | $-461,521,000 | $-460,301,000 | $-216,671,000 |
| Net PPE Purchase And Sale | $-1,695,000 | $-3,098,000 | $-4,315,000 | $-7,858,000 |
| Purchase Of PPE | $-1,695,000 | $-3,098,000 | $-4,315,000 | $-7,858,000 |
| Change In Working Capital | $-50,399,000 | $8,900,000 | $-34,375,000 | $104,405,000 |
| Change In Other Working Capital | $-67,992,000 | $6,064,000 | $-31,055,000 | $95,373,000 |
| Change In Other Current Liabilities | $-7,480,000 | $-6,420,000 | $-4,585,000 | $1,898,000 |
| Change In Payables And Accrued Expense | $1,084,000 | $-6,648,000 | $30,112,000 | $5,337,000 |
| Change In Accrued Expense | $3,552,000 | $-7,354,000 | $25,300,000 | $6,562,000 |
| Change In Payable | $-2,468,000 | $706,000 | $4,812,000 | $-1,225,000 |
| Change In Account Payable | $-2,468,000 | $706,000 | $4,812,000 | $-1,225,000 |
| Change In Prepaid Assets | $19,350,000 | $-11,558,000 | $109,000 | $-3,544,000 |
| Change In Receivables | $4,639,000 | $27,462,000 | $-28,956,000 | $5,341,000 |
| Changes In Account Receivables | $4,639,000 | $27,462,000 | $-28,956,000 | $5,341,000 |
| Other Non Cash Items | $44,663,000 | $36,974,000 | $16,820,000 | $2,922,000 |
| Stock Based Compensation | $14,008,000 | $24,687,000 | $24,908,000 | $26,304,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $-9,917,000 | $-12,130,000 |
| Asset Impairment Charge | $1,694,000 | $0 | - | - |
| Amortization Of Securities | $-3,435,000 | $-9,719,000 | $-9,075,000 | $-364,000 |
| Depreciation Amortization Depletion | $7,324,000 | $7,218,000 | $6,816,000 | $5,690,000 |
| Depreciation And Amortization | $7,324,000 | $7,218,000 | $6,816,000 | $5,690,000 |
| Net Income From Continuing Operations | $-191,086,000 | $-227,461,000 | $-106,793,000 | $-119,204,000 |
| Income Tax Paid Supplemental Data | - | $17,520,000 | $379,000 | $0 |
| Gain Loss On Investment Securities | - | $-32,139,000 | - | $-4,074,000 |
| Common Stock Payments | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-17